Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples
- 11 December 2003
- Vol. 102 (1) , 11-18
- https://doi.org/10.1002/cncr.11904
Abstract
BACKGROUND The performance of two commercially available detection systems for high‐risk HPV (hrHPV), Hybrid Capture 2 (HC2) and in situ hybridization (ISH), were compared on cervical scrapings. METHODS Using general primer (GP)‐mediated GP5+/6+‐polymerase chain reaction (PCR)‐enzyme immunoassay and reverse line blot genotyping, 76 liquid‐based cervical samples were identified with ≥ 1 of the 12 hrHPV types present in the probes of the HC2 and ISH assays. The positivity rate of the assays and the HC2 viral load were determined and related to cytologic findings (n = 76 samples) and histologic findings (n = 43 samples). RESULTS Overall, HC2 scored significantly more samples positive compared with ISH (P < 0.01). Seventy‐four of 76 samples (97%) were positive according to HC2. Forty‐six of 76 samples (61%) were positive according to ISH, including 80% and 70% of samples that were classified cytologically as moderate dysplasia and severe dysplasia, respectively. All women with underlying cervical intraepithelial neoplasia (CIN) lesions and 67% of women without CIN had positive HC2 samples. ISH scored 33%, 66%, 88%, and 73% of samples positive of women with no CIN, Grade 1 CIN (CIN 1), CIN 2, and CIN 3, respectively. The HC2 viral load was significantly higher in women who had a cytologic diagnosis of dysplasia (P < 0.01) and in women who had an underlying diagnosis of CIN (P < 0.01) compared with women who had neither. In addition, the viral load was significantly higher in ISH positive samples compared with ISH negative samples (P < 0.01). CONCLUSIONS An increased HC2 viral load was associated with an increased chance of underlying high‐grade CIN disease in women who tested hrHPV GP5+/6+‐PCR positive. Moreover, although positive ISH results were associated with an increased overall viral load in the sample, the analytic sensitivity of ISH was too low to detect all women with prevalent high‐grade CIN. Cancer (Cancer Cytopathol) 2004;102:11–8. © 2003 American Cancer Society.Keywords
This publication has 20 references indexed in Scilit:
- Human Papillomavirus DNA Testing as an Adjunct to Cytology in Cervical Screening ProgramsArchives of Pathology & Laboratory Medicine, 2003
- Adding a Test for Human Papillomavirus DNA to Cervical-Cancer ScreeningNew England Journal of Medicine, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: A longitudinal study of 3,091 womenInternational Journal of Cancer, 2002
- The causal relation between human papillomavirus and cervical cancerJournal of Clinical Pathology, 2002
- High‐risk HPV testing in women with borderline and mild dyskaryosis: long‐term follow‐up data and clinical relevanceThe Journal of Pathology, 2001
- PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changesJournal of Clinical Pathology, 2000
- Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective studyThe Lancet, 1999
- PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smearsInternational Journal of Cancer, 1996
- Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancerThe Lancet, 1992